# Zevra Therapeutics Inc. (ZVRA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.40, market value $736 million.

## Valuation
- **P/E (trailing): 13.3×** (5-yr avg 6.6×, 3-yr avg 6.6×). Zevra Therapeutics Inc. trades at 13.3× trailing earnings, well above its own five-year average of 6.6×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 11.5×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.07**. A PEG of 0.07 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 5.4×**. Each dollar of revenue is priced at 5.4×.
- **Price / book: 3.4×**. The shares trade at 3.4× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 8.8×**. Enterprise value is 8.8× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 4.4%** (5-yr avg -8.2%). Free cash flow equals 4.4% of the market value, above its five-year average of -8.2%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 7.5%**. The inverse of the P/E: 7.5% of the price is earned each year.

## Profitability
- **Operating margin: 60.5%**. 60.5% of revenue is left after running the business, an exceptional level.
- **Net margin: 78.2%**. 78.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 53.8%**. A 53.8% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 42.2%**. Return on all capital, debt included, is 42.2%: comfortably above what that capital costs.
- **Return on assets: 20.5%**. Each dollar of assets produces 20.5% of profit.

## Growth
- **Revenue growth (1 yr): 350.9%** (3-yr 118.8%/yr, 5-yr 51.6%/yr). Revenue grew 350.9% over the last year, against 51.6% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 159.2%**. Earnings per share rose 159.2%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.40**. Debt is 0.40 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Zevra Therapeutics Inc. holds more cash than debt.
- **Altman Z-score: 3.80**. A Z-score of 3.80 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Zevra Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Zevra Therapeutics Inc.; the consensus is strong_buy, with an average price target of $25.00 (+102% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 38.9%** (YTD 38.4%, 3-mo 16.9%). The shares are up 38.9% over twelve months including dividends.
- **From 52-week high: -17.5%** (73.2% above the low). Trading 18% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 58**. An RSI of 58 is neutral.
- **Beta (1 yr): 0.76** (volatility 63%). Beta of 0.76 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ZVRA · Page: https://foliofundamentals.com/stocks/zvra

Not investment advice.